News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Recce (RCE) Achieves Milestone With Volume Production Of Antibiotic Compounds To Support Clinical Trials



7/20/2017 9:00:51 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
SYDNEY, Australia - 20 July 2017: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, today announced its new automated manufacturing facility in Sydney is now producing at name-plate standard its antibiotic compounds at volumes in preparation for human clinical trials.

The delivery of the automated manufacturing process, together with the provision of facilities and staff for assurance of quality, is an important corporate and technical milestone as it will ensure sufficient, timely and quality supply of the Company’s synthetic antibiotic compounds, designed for compliance with the high standards of the US Food and Drug Administration’s (FDA) current good laboratory practices (glp).

Recce Executive Chairman Dr Graham Melrose said, “I am delighted with this on-schedule milestone towards addressing the urgent global challenges of resistant superbugs”.

The automated process, which uses the latest bioreactor technology by German Pharmaceutical equipment manufacturer Sartorius Stedim, is producing 1000 ml batches of Recce antibiotic per day or around 50 x 150 ml sterile drip bags per week. This is estimated to be enough to supply Phase I and Phase II human clinical trials.

Recce Chief Chemical Engineer Arthur Kollaras said, “Having our own new facility ensures valuable protection against the costly delays commonly experienced by drug companies, in their efforts to produce, refine or add to the capabilities of their product – limitations recently emphasised by the FDA”.

Recce Quality Manager Dr Justin Ward added, “The achievement has been done at very significant economies from alternative outside contracting – and as well, assured that the intellectual properties and their improvements stay right here in Recce”.

Recce’s manufacturing facility at Macquarie Park in NSW and their quality laboratory in the Technology Park of Bentley in WA have been enhanced by the purchase of specialised, high-quality analytical equipment and each will remain totally dedicated to the production and quality of Recce antibiotics.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES